Factor V Leiden mutation and the risks for thromboembolic disease: A clinical perspective

Annals of Internal Medicine

Volumn 127, Issue 10, 1997, Pages 895-903

  Price, Daniel T ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROTEIN C; PROTEIN S;

ANTICOAGULATION; DECISION MAKING; FEMALE; HOMOCYSTINURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; THROMBOEMBOLISM;

EID: 0030667686     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-10-199711150-00007     Document Type: Review

References (93)

1. Schafer AI. The hypercoagulable states. Ann Intern Med. 1985;102:814-28.
2. Nachman RL, Silverstein R. Hypercoagulable states. Ann Intern Med. 1993; 119:819-27.
3. Heijboer H, Brandjes DP, BOIIer HR, Sturk A, ten Gate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deepvein thrombosis. N Engl J Med. 1990:323:1512-6.
4. Miletich JP. Prescott SM, White R, Majerus PW, Bovill EG. Inherited predisposition to thrombosis. Cell. 1993;72:477-80.
5. Dahlbäck B, Carlsson M, Svensson Pi. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sei USA. 1993:90:1004-8.
6. Svensson PJ. Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med. 1994;330:517-22.
7. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet. 1993:342:1503-6.
8. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sei USA. 1994;91:1396-400.
9. Bertina RM, Koeleman B, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994:369:64-7.
10. Zoller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet. 1994; 343:1536-8.
11. Sun X, Evatt B, Griffin JH. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood. 1994;83:3120-5.
12. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single pointmutation at Arg506 of factor V. Lancet. 1994;343:1535-6.
13. Zoller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994:94:2521-4.
14. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995:85:1504-8.
15. Ridker PM. Hennekens CH. Lindpaintner K. Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med. 1995;332:912-7.
16. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpaintner K, Hennekens CH. Factor V Leiden and recurrent idiopathic venous thromboembolism. Circulation. 1995:92:2800-2.
17. Simioni P, Prandoni P, Lensing AW, Scudeller A, Sardella C, Prins MH, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-»Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med. 1997:336:399-403.
18. Vandenbroucke JP, Koster T, Briet E. Reitsma PH, Bertina RM. Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994:344:1453-7.
19. Bloemenkamp KW, Rosendaal FR, Heimerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deepvein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet. 1995:346:1593-6.
20. Rintelen C, Mannhalter C, Ireland H, Lane DA, Knobl P, Lechner K, et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol. 1996:93:487-90.
21. Hellgren M, Svensson P, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol. 1995;173:210-3.
22. Bokarewa Ml, Bremme K, Blomback M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol. 1996:92:473-8.
23. Hirsch DR, Mikkola KM, Marks PW, Fox EA. Dorfman DM, Ewenstein BM, et al. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996:131:1145-8.
24. Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein Cdeficient patients. The French Network on the behalf of INSERM. Blood. 1995:86:219-24.
25. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-defident families. Blood. 1994:84:1031-5.
26. Zoller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein 5. Blood. 1995:85:3518-23.
27. Koeleman BP, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: an additional risk factor for thrombosis in protein S deficient families? Thromb Haemost. 1995,74:580-3.
28. Mandel H, Brenner B, Berant M, Rosenberg N, Lanir N, Jakobs C, et al. Coexistence of hereditary homocystinuria and factor V Leiden-effect on thrombosis. N Engl J Med. 1996:334:763-8.
29. Ridker PM. Hennekens CH, Selhub J. Miletich JP. Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risks of future venous thromboembolism. Circulation. 1997:95:1777-82.
30. Dahlbäck B. Are we ready for factor V Leiden screening? Lancet. 1996:347: 1346-7.
31. Rosendaal FR. Oral contraceptives and screening for factor V Leiden [Letter]. Thromb Haemost. 1996:75:524-5.
32. de Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost. 1994:72:880-6.
33. Tosetto A, Rodeghiero F. Diagnosis of ARC resistance in patients on oral anticoagulant therapy [Letter]. Thromb Haemost. 1995:73:732-3.
34. Cadroy Y, Sie P, Alhenc-Gelas M, Aiach M. Evaluation of APC resistance in the plasma of patients with Q506 mutation of factor V (factor V Leiden) and treated with oral anticoagulants [Letter). Thromb Haemost. 1995;73: 734-5.
35. Halbmeyer WM, Haushofer A, Schon R, Fischer M. Influence of lupus anticoagulant in a commercially available kit for APC-resistance [Letter]. Thromb Haemost. 1994;72:643-51.
36. Gilmore G, Thorn J, Baker Rl. Diagnosis of APC resistance in patients on standard or low molecular weight heparin [Letter]. Thromb Haemost. 1996; 75:372-3.
37. Le DT, Griffin JH, Greengard JS, Mujumdar V, Rapaport SI. Use of a generally applicable tissue factor-dependent factor V assay to detect activated protein C-resistant factor Va in patients receiving warfarin and in patients with a lupus anticoagulant. Blood. 1995;85:1704-11.
38. Rees DC Cox M, Clegg JB. World distribution of factor V Leiden. Lancet. 1995:346:1133-4.
39. Ridker PM. Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA. 1997:277:1305-7.
40. Mannucci PM, Duca F, Peyvandi F, Tagliabue I, Merati G, Martinelli I, et al. Frequency of factor V Arg506 Gin in Italians [Letter]. Thromb Haemost. 1996:75:694.
41. Chan LC. Bourke C, Lam CK, Liu HW, Brookes S, Jenkins V, et al. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors-correlation with absence of Arg506-Gln mutation of factor V gene [Letter]. Thromb Haemost. 1996;75:522-3.
42. Fujimura H, Kambayash J, Monden M, Kalo H. Miyata T. Coagulation factor V Leiden mutation may have a racial background [Letter]. Thromb Haemost. 1995:74:1381-2.
43. Burkitt DP. Varicose veins, deep vein thrombosis, and haemorrhoids: epidemiology and suggested aetiology. BMJ. 1972:2:556-61.
44. Nathwani AC, Tuddenham EG. Epidemiology of coagulation disorders. Baillieres Clin Haemotol. 1992:5:383-439.
45. Griffin JH, Evatt B, Wideman C, Fernandez JA. Anticoagulant protein C pathway defective in the majority of thrombophilic patients. Blood. 1993;82: 1989-93.
46. Ridker PM, Glynn RJ, Miletkh JP, Goldhaber SZ, Stampfer Ml. Hennekens CH. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med. 1997; 126:528-31.
47. den Heijer M, Blom HJ, Gerrits WB. Rosendaal FR, Haak HL, Wijermans PW, et al. Is hyperhomocysteinaemia a risk factor for recurrent thrombosis? Lancet. 1995:345:882-5.
48. den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med. 1996:334:759-62.
49. Falcon CR, Cattaneo M, Panzerl D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb. 1994;14:1080-3.
50. Bienvenu T, Ankri A, Chadefaux B, Kamoun P. [Plasma homocysteine assay in the exploration of thrombosis in young subjects.) Presse Med. 1991; 20:985-8.
51. Brattstrom L, Tengborn L, Lagerstedt C, Israelsson B, Hultberg B. Plasma homocysteine in venous thromboembolism. Haemostasis. 1991;21:51-7.
52. Amundsen T, Ueland PM, Waage A. Plasma homocysteine levels in patients with deep venous thrombosis. Arterioscler Thromb Vase Biol. 1995;15: 1321-3.
53. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med.J (Clin Res Ed). 1986;292:526.
54. Venous thromboembolic disease and combined oral contraceptives: results of the international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995:346:1575-82.
55. Pabinger l, Schneider B. Thrombotic risk of women with hereditary antithrombin 111-, protein C- and protein S-deficiency taking oral contraceptive medication. The GTH Study Group on Natural Inhibitors. Thromb Haemost. 1994;71:548-52.
56. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995; 346:1582-8.
57. Bokarewa Ml, Falk G, Sten-Linder M, Egberg N. Blomback M, Bremme K. Thrombotic risk factors and oral contraception. J Lab Clin Med. 1995; 126: 294-8.
58. Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C: influence of oral contraceptives and sex. Thromb Haemost. 1995; 73:402-4.
59. Olivary O, Friso S, Manzato F, Guella A, Bernardl F. Lunghi B, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol. 1995:91:465-70.
60. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy. A report from the Boston Combined Surveillance Program, Boston University Medical Center. N Engl J Med. 1974;290:15-9.
61. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA. 1979:242:1150-4.
62. Natchigall LE. Natchigall RH, Natchigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol. 1979;54:74-9.
63. Devor M, Barrett-Connor E, Renvall M, Feigal D Jr, Ramsdell J. Estrogen replacement therapy and risk of venous thrombosis. Am J Med. 1992; 92:275-282.
64. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P. Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-80.
65. Jick H, Derby LE, Myers MW. Vasilakis C, Newton KM. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996:348:981-3.
66. Grodstein F, Stampfer MJ. Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, et al. Prospective study of exogenous hormones and risk of pulmonary embolism. Lancet. 1996:348:983-7.
67. Sachs BP, Brown DA, Driscoll SG, Schulman E, Acker D, Ransil BJ, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med. 1987;316:667-72.
68. Sipes SL, Weiner CP. Venous thromboembolic disease in pregnancy. Semin Perinatol. 1990:14:103-18.
69. Stirling Y, Woolf L, North WR, Seghatchian MJ, Meade TW. Haemostasis of normal pregnancy. Thromb Haemost. 1984;52:176-82.
70. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologie protein S levels are decreased during pregnancy. Blood. 1986;68:881-5.
71. Friederich PW, Sanson B, Simoni P, Zanardi S, Huisman MV. Kindt l, et al. Frequency of pregnancy-related venous thrombembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med. 1996; 125:955-60.
72. Rai R, Regan L, Hadley E, Dave M, Cohen H. Second-trimester pregnancy loss is associated with activated protein C resistance. Br J Haemotol. 1996; 92:489-90.
73. Gumming AM, Tait RC, Fildes S. Yoong A, Keeney S, Hay CR. Development of resistance to activated protein C during pregnancy. Br J Haematol. 1995:90:725-7.
74. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villata S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996:125:1-7.
75. Rintelen C, Pabinger I, Knobl P, Lechner K, Mannhalter C. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost. 1996:75:229-32.
76. Holm J, Zoller B, Svensson P, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C [Letter]. Lancet. 1994:344:952-3.
77. Halbmayer WM, Haushofer A, Schon R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coagul Fibrinolysis. 1994:5:51-7.
78. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischémie stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke. 1995:26: 885-90.
79. Albucher JF. Guiraud-Chaumeil B, Choller f, Cadroy Y, Sie P. Frequency of resistance to activated protein C due to factor V mutation in young patients with ischémie stroke [Letter]. Stroke. 1996:27:766-7.
80. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, et al. Myocardial infarction. Arg 506 to Gin factor V mutation, and activated protein C resistance [Letter]. Lancet. 1995:345:321.
81. Samani NJ, Lodwick D, Martin D, Kimber P. Resistance to activated protein C and risk of premature myocardial infarction [Letter]. Lancet. 1995; 344:1709-10.
82. Demarmels Biasiutti F, Merlo C, Furlan M, Sulzer I, Binder BR, Lammle B. No association of APC resistance with myocardial infarction. Blood Coagul Fibrinolysis. 1995:6:456-9.
83. Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 G-»A mutation with resistance to activated protein C being a risk factor for coronary artery disease and myocardial infarction. J Mol Med. 1995:73:521-4.
84. Press RD, Liu XV, Beamer N, Coull BM. Ischémie stroke in the elderly. Role of common factor V mutation causing resistance to activated protein C. Stroke. 1996:27:44-8.
85. Zuber M, Toulon P, Mas JL Resistance to activated protein C in cerebral thromboembolism: a case control study. Cerebrovascular Disease. 199~5;5: 189.
86. Cushman M, Bhushan F, Bovill E, Tracy R. Plasma resistance to activated protein C in venous and arterial thrombosis [Letter). Thromb Haemost. 1994; 72:647.
87. Prevention of venous thrombosis and pulmonary embolism. NIH Consensus Development. JAMA. 1986:256:744-9.
88. Anderson FA Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med. 1991:151:933-8.
89. Kniffin WD Jr, Baron JA, Barren J, Birkmeyer JD, Anderson FA The epidemiology of diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Wed. 1994:154:861-6.
90. Crowther MA, Hayward CP, Hamid C, Johnston M, Gent M, Levine M. et al. Activated protein C resistance is not associated with postoperative deep vein thrombosis in patients undergoing hip or knee surgery [Abstract]. Blood. 1995;86(Suppl 1):616a.
91. Treffers PE, Huidekoper BL, Weenink GH, Kloosterman GJ. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet. 1983:21:327-31.
92. Vandenbroucke JP, van der Meer FJ, Heimerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ. 1996:313:1127-30.
93. Lee RV. Thromboembolic disease and pregnancy: are all women equal? (Editorial] Ann Intern Med. 1996:125:1001-3.